Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

US drug agency proposes rules to rein in opioid manufacturing

Reprints
US drug agency proposes rules to rein in opioid manufacturing

(Reuters) — The U.S. Drug Enforcement Administration on Tuesday unveiled plans to rein in the amount of opioids that can be manufactured by drugmakers in a given year in an effort to combat the deadly opioid epidemic in the United States.

The DEA’s proposed changes to its regulations over addictive drug manufacturing quotas were formally announced by Attorney General Jeff Sessions in a speech on Tuesday.

“Under this proposed new rule, if DEA believes that a company’s opioids are being diverted for misuse, then they will reduce the amount of opioids that company can make,” Mr. Sessions said in prepared remarks.

The new regulatory plan comes after the state of West Virginia sued the DEA in December over its drug quota rules, arguing the agency’s policy wrongfully sets manufacturing quotas based on the amounts of pills that drugmakers expect to sell, not on legitimate medical needs.

That approach, the state argued, has contributed to the growing addiction problem and the illegal diversion of pain medication, while caving to the interests of the drug industry.

“We must end senseless death in West Virginia,” state Attorney General Patrick Morrisey said in a statement. “The reform sought by DEA proves the impact of our lawsuit is still reverberating in Washington and producing real results capable of ending the oversupply of deadly and addictive painkillers that has killed far too many.”

The new DEA proposal calls for the government to take into account the potential for diversion of the drugs or the illegal distribution into illicit channels.

It also would require the DEA to take into account input from important stakeholders, including states and the components of the U.S. Department of Health and Human Services, such as the Food and Drug Administration, the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services, when setting quotas.

The unveiling of the proposal on Tuesday comes after federal, state and local law enforcement officials in West Virginia announced a crackdown on an opioid trafficking ring in Huntington, an area known as “ground zero” for the epidemic.

West Virginia is among the hardest-hit states in the country’s opioid crisis.

According to the CDC, 42,000 people died nationwide from opioid overdoses in 2016, the last year with publicly available data.

 

 

Read Next

  • Could national prescription monitoring proposal deter opioid seekers?

    Buried deep in President Donald Trump’s strategy for managing the opioid crisis is a proposal to create a national prescription drug monitoring program — a database that would cross state lines and limit access to medications for people who live close to interstate borders.